Inventor · disambiguated record
Marc Feldmann
Also filed as: FELDMANN MARC
20 granted patents·27 pending applications·250 citations·filing 1991–2023
95Inventor score
Files withKENNEDY INST OF RHEUMATOLOGY10KENNEDY RHEUMATOLOGY INST10180 THERAPEUTICS LP7FELDMANN MARC3THE KENNEDY TRUST FOR RHEUMATOLOGY RES2
Top patents by PatentIndex Score
47 records- 0195US7846442B2Methods of treating rheumatoid arthritis with an anti-TNF-alpha antibodies and methotrexateKENNEDY RHEUMATOLOGY INST·Filed 2005·Granted Dec 7, 2010·26 cites·22 claims
- 0294US7838489B2Methods of treating rheumatoid arthritis with p75 TNF-alpha receptor and methotrexateKENNEDY RHEUMATOLOGY INST·Filed 2008·Granted Nov 23, 2010·20 cites·10 claims
- 0384US5633145ATNFα receptor-derived binding proteinKENNEDY RHEUMATOLOGY INST·Filed 1991·Granted May 27, 1997·60 cites·9 claims
- 0482US8298537B2Concomitant treatment of rheumatoid arthritis with anti-TNF-α antibodies and methotrexateFELDMANN MARC·Filed 2012·Granted Oct 30, 2012·5 cites·30 claims
- 0581US11220540B2Methods for reducing post-operative cognitive dysfunction (POCD)THE KENNEDY TRUST FOR RHEUMATOLOGY RES·Filed 2019·Granted Jan 11, 2022·2 cites·15 claims
- 0677US6410588B1Use of cannabinoids as anti-inflammatory agentsKENNEDY RHEUMATOLOGY INST·Filed 1999·Granted Jun 25, 2002·43 cites·7 claims
- 0775US8383120B2Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexateKENNEDY RHEUMATOLOGY INST·Filed 2012·Granted Feb 26, 2013·1 cites·19 claims
- 0874US11613570B2Method of treating dupuytren's disease using a pre-filled syringe180 THERAPEUTICS LP·Filed 2022·Granted Mar 28, 2023·0 cites·2 claims
- 0974US2023220060A1Method of treating early stage dupuytren's disease180 THERAPEUTICS LP·Filed 2023·Application pending·0 cites
- 1072US12325744B2Methods for reducing post-operative cognitive dysfunction (POCD)THE KENNEDY TRUST FOR RHEUMATOLOGY RES·Filed 2021·Granted Jun 10, 2025·0 cites·12 claims
- 1172US11400154B2Method of treating a localized fibrotic disorder using an IL-33 antagonist180 THERAPEUTICS LP·Filed 2019·Granted Aug 2, 2022·0 cites·18 claims
- 1270US2011123543A1TNFalpha antagonists and methotrexate in the treatment of TNF-mediated diseaseKENNEDY INST OF RHEUMATOLOGY·Filed 2009·Application pending·0 cites
- 1370US2011014188A1TNFalpha antagonists and methotrexate in the treatment of TNF-mediated diseaseKENNEDY INST OF RHEUMOTOLOGY·Filed 2009·Application pending·0 cites
- 1468US10500273B2Method of treating a localized fibrotic disorder using an IL-33 antagonistLARSEN GLENN·Filed 2016·Granted Dec 10, 2019·1 cites·13 claims
- 1568US7915009B2Activation and inhibition of the immune systemKENNEDY RHEUMATOLOGY INST·Filed 2000·Granted Mar 29, 2011·4 cites·7 claims
- 1668US5958409AMethod for treating multiple sclerosisKENNEDY INST OF RHEUMATOLOGY·Filed 1993·Granted Sep 28, 1999·26 cites·15 claims
- 1768US5863786ANucleic acid encoding modified human tnfα (tumor necrosis factor alpha) receptorKENNEDY RHEUMATOLOGY INST·Filed 1995·Granted Jan 26, 1999·30 cites·8 claims
- 1867US2009263388A1Methods of preventing or treating cardiovascular, cerebrovascular and thrombotic disorders with tumor necrosis factor antagonistsKENNEDY INST OF RHEUMATOLOGY·Filed 2009·Application pending·0 cites
- 1966US2021386855A1Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist180 THERAPEUTICS LP·Filed 2021·Application pending·0 cites
- 2065US2025352477A1Formulations and oral dosage forms of lipophilic agentsCANNBIOREX PHARMA LTD·Filed 2023·Application pending·0 cites
- 2164US7390630B1Method of identifying a compound that selectively inhibits cytokine-stimulated T cell induced production of TNF-alpha by monocytesKENNEDY RHEUMATOLOGY INST·Filed 2000·Granted Jun 24, 2008·3 cites·4 claims
- 2263US12344667B2Method of treating early stage Dupuytren's disease180 THERAPEUTICS LP·Filed 2017·Granted Jul 1, 2025·0 cites·2 claims
- 2360US6770279B1TNFα antagonists and cyclosporin in therapy of rheumatoid arthritisKENNEDY INST OF RHEUMATOLOGY·Filed 1998·Granted Aug 3, 2004·18 cites·2 claims
- 2460US2011098226A1Small molecular weight TNF receptor multimeric moleculeKENNEDY INST OF RHEUMATOLOGY·Filed 2009·Application pending·0 cites
- 2559US2013064816A1TNF-alpha ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASEFELDMANN MARC·Filed 2012·Application pending·0 cites
- 2659US2004228863A1Treatment of tumor necrosis factor-mediated diseasesKENNEDY INST OF RHEUMATOLOGY·Filed 2004·Application pending·0 cites
- 2753US2008124322A1Activation and inhibition of the immune systemFOXWELL BRIAN·Filed 2007·Application pending·0 cites
- 2853US2002136723A1Anti-TNF antibodies and methotrexate in the treatment of autoimmune diseaseKENNEDY INST OF RHEUMATOLOGY·Filed 2001·Application pending·0 cites
- 2952US2002010180A1TNFalpha antagonists and methotrexate in the treatment of TNF-mediated diseaseKENNEDY INST OF RHEUMATOLOGY·Filed 2001·Application pending·0 cites
- 3051US2007031925A1Small molecular weight TNF receptor multimeric moleculeCHERNAJOVSKY YUTI·Filed 2006·Application pending·0 cites
- 3147US2004241152A1Methods for inducing an immune response with an elevated th1/th2 ratio, by intracellular induction of nfkappabFiled 2002·Application pending·0 cites
- 3247US2014030218A1Treatment And ScreeningUDALOVA IRINA ALEXANDROVNA·Filed 2012·Application pending·0 cites
- 3345US7651857B2Methods for enhancing antigen presentationKENNEDY RHEUMATOLOGY INST·Filed 2001·Granted Jan 26, 2010·0 cites·21 claims
- 3443US7070783B1Small molecular weight TNF receptor multimeric moleculeKENNEDY RHEUMATOLOGY INST·Filed 1999·Granted Jul 4, 2006·5 cites·10 claims
- 3543US2007178099A1Suppression of TNFalpha and IL-12 in therapyKENNEDY INST OF RHEUMATOLOGY·Filed 2007·Application pending·0 cites
- 3643US2003064070A1Multiple administrations of anti-TNF antibodyCENTOCOR INC·Filed 2002·Application pending·0 cites
- 3743US2022023387A1Prophylactic and therapeutic uses of fully reduced forms of hmgb1 in conditions involving organsUNIV OXFORD INNOVATION LTD·Filed 2019·Application pending·0 cites
- 3843US2019225682A1Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody180 THERAPEUTICS LP·Filed 2017·Application pending·0 cites
- 3943US2021260157A1Prophylactic uses of partially or fully reduced forms of hmgb1 prior to injuryUNIV OXFORD INNOVATION LTD·Filed 2019·Application pending·0 cites
- 4041US2002177572A1Viral infection of cellsFiled 2001·Application pending·0 cites
- 4140US2019202907A1Method of treating systemic fibrotic disorders using an il-33/tnf bispecific antibody180 THERAPEUTICS LP·Filed 2017·Application pending·0 cites
- 4240US2006140933A1Compositions and methods for treating rage-associated disordersWYETH AND IMP COLLEGE INNOVATI·Filed 2003·Application pending·0 cites
- 4340US2014005255A1Agonists Of Toll Like Receptor For Treating Cardiovasuclar Disease And ObesityMONACO CLAUDIA·Filed 2011·Application pending·0 cites
- 4439US7608262B2Methods of preventing or treating thrombosis with tumor necrosis factor antagonistsKENNEDY INST OF RHEUMATOLOGY·Filed 1996·Granted Oct 27, 2009·6 cites·1 claims
- 4537US2021285017A1Method and system for improving the greenhouse gas emission reduction performance of biogenic fuels, heating mediums and combustion materials and/or for enriching agricultural areas with carbon-containing humusFELDMANN MARC·Filed 2017·Application pending·0 cites
- 4635US2002039734A1Compositions, kits, and methods for identification and modulation of T helper-1 and T helper-2 cells and diseases associated therewithFiled 2001·Application pending·0 cites
- 4729US2002068057A1Treatment of autoimmune and inflammatory disordersFiled 1994·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Marc Feldmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →